QuEra Computing, a leader in neutral-atom quantum computing, and Quantum Intelligence Corp. (QIC), a South Korean innovator in AI-driven drug development, announced a strategic partnership to accelerate drug discovery. The collaboration will integrate QuEra’s advanced quantum computing technology with QIC’s QUEST platform, aiming to enhance the accuracy, speed, and efficiency of drug development processes.
QuEra’s neutral-atom quantum computers offer significant computing power, enabling dynamic qubit manipulation for flexible quantum computations. These capabilities will be leveraged to boost QIC’s AI algorithms, which predict drug behavior and potential side effects by analyzing electronic charge distributions in molecules. The partnership is expected to significantly reduce risks and improve the safety and effectiveness of new treatments.
Dr. Hwanho Choi, CEO of QIC, emphasized that this collaboration positions QIC at the forefront of merging quantum and AI technologies in the biopharmaceutical industry. QuEra’s Chief Commercial Officer, Yuval Boger, highlighted the partnership as a crucial step in applying quantum computing to revolutionize drug discovery.
QuEra and QIC’s joint efforts are poised to transform traditional drug development, setting a new standard in the industry. For additional information, you can access the press release provided by QuEra Computing here.
August 13, 2024
